VERU - This Growth Stock Has Soared Over 200% Year to Date -- Is It a Buy?
Pharmaceutical companies can grab the attention of investors through positive clinical studies and expectations of a potential U.S. Food and Drug Administration (FDA) approval. On the other hand, investors don't typically care for a quarterly earnings miss.
So what happens to a company's stock when all three of these pieces of news hit at the same time? Let's see in the case of Veru (NASDAQ: VERU) . It's taken a solid turn in one direction. But is it a healthy stock for long-term investors?
Image source: Getty Images.
For further details see:
This Growth Stock Has Soared Over 200% Year to Date -- Is It a Buy?